Center for Novel Therapeutics for HIV-Associated Cognitive Disorders

Summary

Principal Investigator: Justin C McArthur
Abstract: DESCRIPTION (provided by applicant): JHU NIMH Center for novel therapeutics for HIV-associated cognitive disorders. HIV-associated neurocognitive disorders (HAND) remain very prevalent, even among aviremic HIV+ individuals who treated with highly active antiretroviral treatments. HIV-related neuroscience research at Johns Hopkins University has focused on this challenging problem, exploring the issue of sustained CNS inflammation as a critical pathogenic mechanism for neurological damage. Despite the tremendous efforts to understand the mechanisms underlying the persistence of HAND, no definitive adjunctive therapeutics have yet entered clinical practice. There is also an unfilled need to develop surrogate markers and more robust and simpler screening instruments for HAND, to allow for earlier detection, for tracking of the course of HAND, and improving the efficiency of clinical trials. Collaborations at Johns Hopkins had been limited by the lack of a central organizing structure for this type of research, and resources to facilitate cross disciplinary and translational research. The JHU NIMH Center has addressed these needs over the past 5 years and has provided a resource to catalyze interdisciplinary research in HIV neuroscience, with the aim of leading to new therapies. The goals of the renewal application of the JHU NIMH Center are to: 1. To facilitate collaborative research in HIV-related neuroscience with the goal of developing a definitive therapy for HIV associated cognitive disorders based on targeting sustained CNS inflammation. 2. To increase resources for HIV-related neuroscience research at JHU and to enhance the productivity of HiV-related neuroscience research locally, nationally and internationally. 3. To encourage high-risk, innovative developmental research in Neuro-AIDS, especially of a cross-disciplinary nature with the specific aim of encouraging investigators (junior or senior) into this field. 4. To use focused medium throughput screening, using in vitro models to identify novel compounds useful for treatment of HIV-associated cognitive dysfunction with the over-arching theme of reducing the sustained CNS inflammation that we believe underlies the development of HAND. 5. To identify and validate surrogate biomarkers based on proteomics and lipomics.
Funding Period: 2005-07-01 - 2016-06-30
more information: NIH RePORT

Top Publications

  1. ncbi HIV-associated opportunistic infections of the CNS
    Ik Lin Tan
    HIV Neuroscience Program, Johns Hopkins University, Baltimore, MD 21287, USA
    Lancet Neurol 11:605-17. 2012
  2. pmc Determinants of epidermal nerve fibre density in antiretroviral-naïve HIV-infected individuals
    Cm Shikuma
    University of Hawaii, Honolulu, HI 96816, USA
    HIV Med 13:602-8. 2012
  3. pmc De novo generation of cells within human nurse macrophages and consequences following HIV-1 infection
    Suzanne Gartner
    Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, United States of America
    PLoS ONE 7:e40139. 2012
  4. pmc Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz
    Luis B Tovar-y-Romo
    Department of Neurology, Richard T Johnson Division of Neuroimmunology and Neurological Infections, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
    J Pharmacol Exp Ther 343:696-703. 2012
  5. pmc Ketone bodies protection against HIV-1 Tat-induced neurotoxicity
    Liang Hui
    Department of Pharmacology, Physiology and Therapeutics, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, North Dakota, USA
    J Neurochem 122:382-91. 2012
  6. pmc Treatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance
    Daniel M Harrison
    Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Mult Scler 18:202-9. 2012
  7. pmc The Role of ATP-Binding Cassette Transporters in Neuro-Inflammation: Relevance for Bioactive Lipids
    Gijs Kooij
    Blood Brain Barrier Research Group, Department of Molecular Cell Biology and Immunology, VU University Medical Center Amsterdam, Netherlands
    Front Pharmacol 3:74. 2012
  8. pmc Neurologic disorders incidence in HIV+ vs HIV- men: Multicenter AIDS Cohort Study, 1996-2011
    Farrah J Mateen
    Department of Neurology, The Johns Hopkins Hospital, Baltimore, MD, USA
    Neurology 79:1873-80. 2012
  9. pmc Atypical manifestations and poor outcome of herpes simplex encephalitis in the immunocompromised
    Ik L Tan
    Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA
    Neurology 79:2125-32. 2012
  10. ncbi HIV-associated neurological disorders: a guide to pharmacotherapy
    Ik L Tan
    Department of Neurology, School of Medicine, Johns Hopkins University, Baltimore, MD 21287 7613, USA
    CNS Drugs 26:123-34. 2012

Research Grants

  1. Emory Alzheimer's Disease Center
    Allan I Levey; Fiscal Year: 2013

Detail Information

Publications63

  1. ncbi HIV-associated opportunistic infections of the CNS
    Ik Lin Tan
    HIV Neuroscience Program, Johns Hopkins University, Baltimore, MD 21287, USA
    Lancet Neurol 11:605-17. 2012
    ....
  2. pmc Determinants of epidermal nerve fibre density in antiretroviral-naïve HIV-infected individuals
    Cm Shikuma
    University of Hawaii, Honolulu, HI 96816, USA
    HIV Med 13:602-8. 2012
    ....
  3. pmc De novo generation of cells within human nurse macrophages and consequences following HIV-1 infection
    Suzanne Gartner
    Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, United States of America
    PLoS ONE 7:e40139. 2012
    ..These phenomena have far-reaching implications, and elicit new perspectives regarding HIV pathogenesis and T-cell and hematopoietic cell development...
  4. pmc Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz
    Luis B Tovar-y-Romo
    Department of Neurology, Richard T Johnson Division of Neuroimmunology and Neurological Infections, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
    J Pharmacol Exp Ther 343:696-703. 2012
    ..These findings demonstrate that the 8-OH metabolite of EFV is a potent neurotoxin and highlight the importance of directly determining the effects of antiretroviral drugs and drug metabolites on neurons and other brain cells...
  5. pmc Ketone bodies protection against HIV-1 Tat-induced neurotoxicity
    Liang Hui
    Department of Pharmacology, Physiology and Therapeutics, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, North Dakota, USA
    J Neurochem 122:382-91. 2012
    ..Ketogenic strategies have been used clinically for treatment of neurological disorders and our current results suggest that similar strategies may also provide clinical benefits in the treatment of HAND...
  6. pmc Treatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance
    Daniel M Harrison
    Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Mult Scler 18:202-9. 2012
    ..The long-term benefit of this stabilization followed by conventional therapy has not been explored...
  7. pmc The Role of ATP-Binding Cassette Transporters in Neuro-Inflammation: Relevance for Bioactive Lipids
    Gijs Kooij
    Blood Brain Barrier Research Group, Department of Molecular Cell Biology and Immunology, VU University Medical Center Amsterdam, Netherlands
    Front Pharmacol 3:74. 2012
    ..A thorough understanding of these events may form the basis for the development for selective treatment modalities to dampen the neuro-inflammatory attack in MS and thereby reducing tissue damage...
  8. pmc Neurologic disorders incidence in HIV+ vs HIV- men: Multicenter AIDS Cohort Study, 1996-2011
    Farrah J Mateen
    Department of Neurology, The Johns Hopkins Hospital, Baltimore, MD, USA
    Neurology 79:1873-80. 2012
    ..To study the incidence and pattern of neurologic disorders in a large cohort of HIV-positive men, compared with HIV-negative men, in the era of highly active antiretroviral therapy (HAART)...
  9. pmc Atypical manifestations and poor outcome of herpes simplex encephalitis in the immunocompromised
    Ik L Tan
    Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA
    Neurology 79:2125-32. 2012
    ..To characterize clinical features, neuroimaging, and outcomes of herpes simplex encephalitis (HSE) in immunocompromised individuals...
  10. ncbi HIV-associated neurological disorders: a guide to pharmacotherapy
    Ik L Tan
    Department of Neurology, School of Medicine, Johns Hopkins University, Baltimore, MD 21287 7613, USA
    CNS Drugs 26:123-34. 2012
    ..There is an urgent need to better define the therapeutic guidelines for the prevention and treatment of HAND...
  11. pmc Protein-free efavirenz concentrations in cerebrospinal fluid and blood plasma are equivalent: applying the law of mass action to predict protein-free drug concentration
    L B Avery
    Department of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Antimicrob Agents Chemother 57:1409-14. 2013
    ..As CSF penetration of ARVs may increase our understanding of HIV-associated neurological dysfunction and antiretroviral effect, assessment of protein-free CSF concentrations of other highly protein-bound ARVs is warranted...
  12. pmc Longitudinal neuropsychological test performance among HIV seropositive individuals in Uganda
    Ned Sacktor
    Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
    J Neurovirol 19:48-56. 2013
    ..Possible reasons for this include practice effects among the no-ART group as well as improvements in their mood and overall quality of life...
  13. pmc Endolysosome involvement in HIV-1 transactivator protein-induced neuronal amyloid beta production
    Xuesong Chen
    Department of Pharmacology, Physiology and Therapeutics, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, ND, USA
    Neurobiol Aging 34:2370-8. 2013
    ..Together, our findings suggest that HIV-1 Tat increases neuronal Aβ generation and thereby contributes to the development of AD-like pathology in HIV-1-infected individuals by disturbing endolysosome structure and function. ..
  14. pmc Inhibition of microglia activation as a phenotypic assay in early drug discovery
    Mariana Figuera-Losada
    1Brain Science Institute NeuroTranslational Drug Discovery Program, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    J Biomol Screen 19:17-31. 2014
    ....
  15. pmc HIV subtype is not associated with dementia among individuals with moderate and advanced immunosuppression in Kampala, Uganda
    Ned Sacktor
    Department of Neurology, Johns Hopkins Bayview Medical Center, 301 Building, Suite 2100, 4940 Eastern Ave, Baltimore, MD, 21224, USA
    Metab Brain Dis 29:261-8. 2014
    ..There was no association between HIV subtype and dementia among HIV+ individuals with moderate and advanced immunosuppression. Future studies should be performed to confirm these results...
  16. pmc A lipid storage-like disorder contributes to cognitive decline in HIV-infected subjects
    Veera Venkata Ratnam Bandaru
    From the Department of Neurology, Division of Neuroimmunology and Neurological Infections V V R B, N S, J C M, C P, P C, N J H, and the Department of Psychiatry N J H, The Johns Hopkins University, School of Medicine, Baltimore, MD the Department of Health Sciences Research M M M, Division of Epidemiology, The Mayo Clinic, Rochester, MN HIV Neurobehavioral Research Program and Department of Psychiatry I G, S L, School of Medicine, University of California, San Diego, La Jolla the Department of Psychiatry L C, S M, University of Hawaii, John A Burns School of Medicine, Honolulu and the Department of Neurology V W, Specialized Neurosciences Research Program, University of Puerto Rico Medical Sciences Campus, San Juan
    Neurology 81:1492-9. 2013
    ..In this multicenter cohort study, we sought to identify prognostic and associative metabolic indicators for HIV-associated neurocognitive disorders (HAND)...
  17. pmc A biological perspective of CSF lipids as surrogate markers for cognitive status in HIV
    Norman J Haughey
    Department of Neurology, Division of Neuroimmunology and Neurological Infections, The Johns Hopkins University School of Medicine, Pathology 517, 600 North Wolfe Street, Baltimore, MD, 21287, USA
    J Neuroimmune Pharmacol 8:1136-46. 2013
    ....
  18. pmc A novel computerized functional assessment for human immunodeficiency virus-associated neurocognitive disorder
    Liana S Rosenthal
    Department of Neurology, Johns Hopkins University, 600 North Wolfe Street, Baltimore, MD, 21287, USA
    J Neurovirol 19:432-41. 2013
    ..These results suggest the CAMCI could be a useful objective performance-based functional assessment in patients with HIV. ..
  19. pmc Ceramides predict verbal memory performance in coronary artery disease patients undertaking exercise: a prospective cohort pilot study
    Mahwesh Saleem
    Neuropsychopharmacology Research Group, Sunnybrook Health Sciences Centre, Toronto, Ontario M4N 3M5, Canada
    BMC Geriatr 13:135. 2013
    ..In this study, concentrations of very long chain ceramides (C22:0 and C24:0) were assessed as predictors of changes in verbal memory performance over 1 year in subjects with CAD undertaking cardiac rehabilitation (CR)...
  20. pmc Targeting the glutamatergic system for the treatment of HIV-associated neurocognitive disorders
    Michelle C Potter
    Brain Science Institute NeuroTranslational Drug Discovery Program, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    J Neuroimmune Pharmacol 8:594-607. 2013
    ..These efforts however, are at an early stage where the next steps are dependent on the identification of drug-like inhibitors as well as the development of predictive neuroAIDS animal models...
  21. pmc Predictors of outcome in acute encephalitis
    Kiran T Thakur
    Johns Hopkins Encephalitis Center, Department of Neurology, The Johns Hopkins University School of Medicine, The Johns Hopkins University, Baltimore, MD, USA
    Neurology 81:793-800. 2013
    ..To investigate predictors of outcome in patients with all-cause encephalitis receiving care in the intensive care unit...
  22. pmc Use of a glycolipid inhibitor to ameliorate renal cancer in a mouse model
    Subroto Chatterjee
    Department of Pediatrics, Division of Pediatric Cardiology, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    PLoS ONE 8:e63726. 2013
    ..By linking glycosphingolipid synthesis with tumor growth, renal cancer progression and regression can be evaluated. Thus inhibiting glycosphingolipid synthesis can be a bonafide target to prevent the progression of other types of cancer...
  23. pmc Evaluating sleep and cognition in HIV
    Charlene E Gamaldo
    Department of Neurology, Johns Hopkins University, Baltimore, MD Laboratory of Behavioral Neuroscience, National Institute on Aging, Baltimore, MD Departments of Pathology, Epidemiology, and Medicine, Johns Hopkins University, Baltimore, MD and Department of Psychiatry and Behavioral Medicine, Johns Hopkins University, Baltimore, MD
    J Acquir Immune Defic Syndr 63:609-16. 2013
    ..To examine the relationship between measures of sleep quality and cognitive performance in HIV-positive individuals stable on combination antiretroviral therapy...
  24. pmc Adenosine triphosphate released from HIV-infected macrophages regulates glutamatergic tone and dendritic spine density on neurons
    Luis B Tovar-y-Romo
    Department of Neurology, Richard T Johnson Division of Neuroimmunology and Neurological Infections, Johns Hopkins University School of Medicine, Pathology 517, 600 North Wolfe Street, Baltimore, MD 21287, USA
    J Neuroimmune Pharmacol 8:998-1009. 2013
    ..These data suggest that neuronal function may be depressed in HIV infected individuals by mechanisms that involve macrophage release of ATP that triggers secondary effects on glutamate handling. ..
  25. pmc Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors
    Krupa Shukla
    Department of Neurology and Brain Science Institute, Johns Hopkins University, Baltimore, Maryland 21205, United States
    J Med Chem 55:10551-63. 2012
    ....
  26. pmc A failure to normalize biochemical and metabolic insults during morphine withdrawal disrupts synaptic repair in mice transgenic for HIV-gp120
    Veera Venkata Ratnam Bandaru
    Department of Neurology, Division of Neuroimmunology, Johns Hopkins University School of Medicine, Meyer 6 109, 600 North Wolfe Street, Baltimore, MD 21287, USA
    J Neuroimmune Pharmacol 6:640-9. 2011
    ....
  27. pmc JC virus antibody and viremia as predictors of progressive multifocal leukoencephalopathy in human immunodeficiency virus-1-infected individuals
    Raphael P Viscidi
    Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Clin Infect Dis 53:711-5. 2011
    ..JCV viremia was not predictive of PML, but some patients showed higher anti-JCV immunoglobulin G (IgG) responses 6 months prior to diagnosis...
  28. ncbi Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia
    Melissa J Churchill
    Centre for Virology, The Macfarlane Burnet Institute for Medical Research and Public Health, Melbourne, Victoria, Australia
    Ann Neurol 66:253-8. 2009
    ..Our data indicate that astrocytes can be extensively infected with HIV, and suggest an important role for HIV-infected astrocytes in HIV neuropathogenesis...
  29. pmc Selegiline and oxidative stress in HIV-associated cognitive impairment
    G Schifitto
    University of Rochester, NY, USA
    Neurology 73:1975-81. 2009
    ....
  30. pmc ApoE4 disrupts sterol and sphingolipid metabolism in Alzheimer's but not normal brain
    Veera Venkata Ratnam Bandaru
    Department of Neurology, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Baltimore, MD 21287, USA
    Neurobiol Aging 30:591-9. 2009
    ....
  31. ncbi Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy
    Deanna Cettomai
    Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Arch Neurol 66:255-8. 2009
    ..An efficacious treatment is needed for human immunodeficiency virus (HIV)-infected and uninfected patients with progressive multifocal leukoencephalopathy (PML)...
  32. pmc Serum matrix metalloproteinase levels correlate with brain injury in human immunodeficiency virus infection
    Ann B Ragin
    Department of Radiology, Northwestern University, Chicago, Illinois 60611 2927, USA
    J Neurovirol 15:275-81. 2009
    ..MMPs may influence neurological outcome through involvement in neuroimmune response, blood-brain barrier permeability, leukocyte migration, and MMP-mediated neurotoxicity...
  33. pmc Acetyl-l-carnitine and nucleoside reverse transcriptase inhibitor-associated neuropathy in HIV infection
    V Valcour
    Hawaii AIDS Clinical Research Program, John A Burns School of Medicine, University of Hawaii, Honolulu, HI, USA
    HIV Med 10:103-10. 2009
    ..We present an open-label single-arm pilot study to evaluate changes in intra-epidermal nerve fibre (IENF) density and mitochondrial DNA (mtDNA) copies/cell among subjects treated with 3000 mg ALC daily...
  34. ncbi Nitrosative stress with HIV dementia causes decreased L-prostaglandin D synthase activity
    W Li
    Department of Neurology, Johns Hopkins University, Baltimore, MD, USA
    Neurology 70:1753-62. 2008
    ..However, there are no surrogate markers for the disease, either to identify it de novo or to track its progression, and there is no proven treatment with the exception of antiretroviral drugs...
  35. pmc Converging roles for sphingolipids and cell stress in the progression of neuro-AIDS
    Norman J Haughey
    Department of Neurology, Richard T Johnson Division of Neuroimmunology and Neurological Infections, The Johns Hopkins University School of Medicine, 600 N Wolfe Street, Baltimore, MD 21287, USA
    Front Biosci 13:5120-30. 2008
    ....
  36. ncbi Spanish validation of the HIV dementia scale in women
    V Wojna
    NeuroAIDS SNRP, University of Puerto Rico, Medical Sciences Campus, San Juan, Puerto Rico
    AIDS Patient Care STDS 21:930-41. 2007
    ..0% negative predictive value). The HDS-Spanish translation offers a useful screening tool with value for the identification of Hispanic women at risk of developing HIV-associated symptomatic neurocognitive disturbances...
  37. ncbi Frequency of and risk factors for HIV dementia in an HIV clinic in sub-Saharan Africa
    M H Wong
    School of Medicine, McMaster University, Hamilton, Ontario, Canada
    Neurology 68:350-5. 2007
    ..To measure the frequency and associated risk factors of HIV dementia in an HIV clinic in Kampala, Uganda...
  38. ncbi Denervation of skin in neuropathies: the sequence of axonal and Schwann cell changes in skin biopsies
    Gigi J Ebenezer
    Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21287 7613, USA
    Brain 130:2703-14. 2007
    ....
  39. ncbi Platelet decline: an avenue for investigation into the pathogenesis of human immunodeficiency virus -associated dementia
    Lynn M Wachtman
    Department of Molecular and Comparative Pathobiology, The Johns Hopkins University, Baltimore, Maryland 21287 7609, USA
    Arch Neurol 64:1264-72. 2007
    ..The identification of biomarkers identifying onset of human immunodeficiency virus-associated dementia (HIV-D) is critical for diagnosis and the elucidation of pathophysiologic pathways...
  40. pmc Altered cutaneous nerve regeneration in a simian immunodeficiency virus / macaque intracutaneous axotomy model
    Gigi J Ebenezer
    Department of Neurology, Johns Hopkins University, Baltimore, MD 21287 7609, USA
    J Comp Neurol 514:272-83. 2009
    ....
  41. ncbi Circular compartmentalized microfluidic platform: Study of axon-glia interactions
    Suneil Hosmane
    Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Lab Chip 10:741-7. 2010
    ....
  42. pmc HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study
    R K Heaton
    University of California, San Diego, USA
    Neurology 75:2087-96. 2010
    ....
  43. pmc Rescue of adult hippocampal neurogenesis in a mouse model of HIV neurologic disease
    Myoung Hwa Lee
    Department of Neurology, Johns Hopkins University School of Medicine, 600 N Wolfe St, Meyer 6 113, Baltimore, MD 21287, USA
    Neurobiol Dis 41:678-87. 2011
    ....
  44. pmc A comparison of performance-based measures of function in HIV-associated neurocognitive disorders
    Nishiena S Gandhi
    Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    J Neurovirol 17:159-65. 2011
    ..Newer measures of functional performance can be used to objectively evaluate functional impairment in HAND and validate different levels of HAND...
  45. pmc Impaired neurovascular repair in subjects with diabetes following experimental intracutaneous axotomy
    Gigi J Ebenezer
    Department of Neurology, Johns Hopkins University, Baltimore, MD 21287 7609, USA
    Brain 134:1853-63. 2011
    ..These models are useful tools for the efficient investigation of neurotrophic and regenerative drugs, and also to explore factors that may differentially affect axonal regeneration...
  46. pmc Marked relationship between matrix metalloproteinase 7 and brain atrophy in HIV infection
    Ann B Ragin
    Department of Radiology, Northwestern University, 737 N Michigan Avenue, Suite 1600, Chicago, IL 60611 2927, USA
    J Neurovirol 17:153-8. 2011
    ..MMP-7 was also correlated with measures of virologic and cognitive status...
  47. pmc Osteopontin enhances HIV replication and is increased in the brain and cerebrospinal fluid of HIV-infected individuals
    Amanda Brown
    Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21287 7131, USA
    J Neurovirol 17:382-92. 2011
    ....
  48. ncbi Immune reconstitution is not a prognostic factor in progressive multifocal leukoencephalopathy
    Daniel M Harrison
    Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    J Neuroimmunol 238:81-6. 2011
    ..05). Improved prognosis was seen with higher cerebrospinal fluid (CSF) white blood cell counts and protein levels, but not for gadolinium enhancement and there were no differences in survival for PML versus PML-IRIS...
  49. pmc The human immunodeficiency virus coat protein gp120 promotes forward trafficking and surface clustering of NMDA receptors in membrane microdomains
    Hangxiu Xu
    Department of Neurology, Richard T Johnson Division of Neuroimmunology and Neurological Infections, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    J Neurosci 31:17074-90. 2011
    ..These findings demonstrate that gp120 contributes to synaptic dysfunction in the setting of HIV infection by interfering with NMDA receptor trafficking...
  50. pmc Immune reconstitution inflammatory syndrome in natalizumab-associated PML
    I L Tan
    Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA
    Neurology 77:1061-7. 2011
    ..To study the outcome of patients with multiple sclerosis (MS) and with natalizumab-associated progressive multifocal leukoencephalopathy (PML) and immune reconstitution inflammatory syndrome (IRIS)...
  51. ncbi Relationship of depression and catastrophizing to pain, disability, and medication adherence in patients with HIV-associated sensory neuropathy
    Brendan P Lucey
    Department of Neurology, Michael O Callaghan Federal Hospital, Nellis Air Force Base, NV, USA
    AIDS Care 23:921-8. 2011
    ..These findings suggest that both catastrophizing and depressive symptoms are important factors to consider in the management of pain from HIV neuropathy and adherence to ART...
  52. ncbi Human immunodeficiency virus-associated neurocognitive disorders: Mind the gap
    Justin C McArthur
    NIMH Center for Novel Therapeutics for HIV Associated Cognitive Disorders, Johns Hopkins University, Baltimore, MD, USA
    Ann Neurol 67:699-714. 2010
    ..Novel therapies aimed at persistent central nervous system inflammation will be needed to close this gap...
  53. pmc Biomarkers of neurological status in HIV infection: a 3-year study
    Ann B Ragin
    Department of Radiology, Northwestern University, Chicago, IL 60611, USA
    Proteomics Clin Appl 4:295-303. 2010
    ..To evaluate circulating cytokines and chemokines as correlates of the degree of brain injury in individuals with advanced human immunodeficiency virus (HIV) infection...
  54. ncbi Prevalence of and risk factors for HIV-associated neuropathy in Melbourne, Australia 1993-2006
    K Smyth
    Department of Medicine, Australian National University, Canberra, Australia
    HIV Med 8:367-73. 2007
    ....

Research Grants30

  1. Emory Alzheimer's Disease Center
    Allan I Levey; Fiscal Year: 2013
    ..abstract_text> ..